# Baricitinib for Patients With Intracerebral Hemorrhage

Study · id `cardio:ct-nct06737705` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06737705](<https://clinicaltrials.gov/study/NCT06737705>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06737705

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT06737705. Randomized; single masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2025-08-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT06737705, source copy `cardio:ctgov-nct06737705-2026-06-18`, retrieved 2026-10-31)
- Started: 2025-01-01 (actual) (ClinicalTrials.gov record NCT06737705, source copy `cardio:ctgov-nct06737705-2026-06-18`, retrieved 2026-10-31)
- Primary completion: 2025-08-18 (actual) (ClinicalTrials.gov record NCT06737705, source copy `cardio:ctgov-nct06737705-2026-06-18`, retrieved 2026-10-31)
- Completion: 2025-08-18 (actual) (ClinicalTrials.gov record NCT06737705, source copy `cardio:ctgov-nct06737705-2026-06-18`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06737705, source copy `cardio:ctgov-nct06737705-2026-06-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06737705-2026-06-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Baricitinib for Patients With Intracerebral Hemorrhage
- Acronym: BRIGHT
- Condition: Intracerebral Hemorrhage
- Intervention (Drug): Baritinib
- Lead sponsor: De-zhi Kang
- Lead sponsor class: OTHER
- Collaborator: Fujian Medical University
- Collaborator class: OTHER
- Collaborator: Tianjin Medical University General Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry lists this organization as a collaborator: Tianjin Medical University General Hospital (`cardio:org-tianjin-medical-university-general-hospital`)

## Provenance

Content hash: 846b4f3b82afd1a11884dfb5fc4fcf0ea0cc7f6fbb184279aaeda35ddeab2794
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
